150 related articles for article (PubMed ID: 17663174)
1. [Response to tamoxifen in estrogen receptor-positive cell line MCF-7 is independent of p53 expression].
Shtam TA; Pantina RA; Varfolomeeva EIu; Filatov MV
Vopr Onkol; 2007; 53(2):194-9. PubMed ID: 17663174
[TBL] [Abstract][Full Text] [Related]
2. Can transforming growth factor-beta1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells?
Czeczuga-Semeniuk E; Anchim T; Dziecioł J; Dabrowska M; Wołczyński S
Acta Biochim Pol; 2004; 51(3):733-45. PubMed ID: 15448735
[TBL] [Abstract][Full Text] [Related]
3. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation and tamoxifen resistance in breast cancer.
Elledge RM; Lock-Lim S; Allred DC; Hilsenbeck SG; Cordner L
Clin Cancer Res; 1995 Oct; 1(10):1203-8. PubMed ID: 9815913
[TBL] [Abstract][Full Text] [Related]
5. Pak up your breast tumor--and grow!
Jordan VC
J Natl Cancer Inst; 2006 May; 98(10):657-9. PubMed ID: 16705113
[No Abstract] [Full Text] [Related]
6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
Kilker RL; Hartl MW; Rutherford TM; Planas-Silva MD
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):63-71. PubMed ID: 15544931
[TBL] [Abstract][Full Text] [Related]
8. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
9. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
10. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
[TBL] [Abstract][Full Text] [Related]
12. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
Glaeser M; Niederacher D; Djahansouzi S; Hanstein B; Dittrich R; Beckmann MW; Fasching PA; Ackermann S
Anticancer Res; 2006; 26(1B):735-44. PubMed ID: 16739346
[TBL] [Abstract][Full Text] [Related]
13. Clusterin: a potential target for improving response to antiestrogens.
Toffanin S; Daidone MG; Miodini P; De Cecco L; Gandellini P; Cappelletti V
Int J Oncol; 2008 Oct; 33(4):791-8. PubMed ID: 18813793
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells.
Zhang W; Couldwell WT; Song H; Takano T; Lin JH; Nedergaard M
Cancer Res; 2000 Oct; 60(19):5395-400. PubMed ID: 11034078
[TBL] [Abstract][Full Text] [Related]
15. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
16. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
Girgert R; Hanf V; Emons G; Gründker C
J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line.
Koda M; Jarzabek K; Haczynski J; Knapp P; Sulkowski S; Wolczynski S
Oncol Rep; 2004 Sep; 12(3):517-21. PubMed ID: 15289830
[TBL] [Abstract][Full Text] [Related]
18. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
19. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism.
de Medina P; Payré B; Boubekeur N; Bertrand-Michel J; Tercé F; Silvente-Poirot S; Poirot M
Cell Death Differ; 2009 Oct; 16(10):1372-84. PubMed ID: 19521424
[TBL] [Abstract][Full Text] [Related]
20. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
